NCT05469750

Dalpiciclib Plus Letrozole and Capecitabine

A Single Arm，Multicenter，Open-label Study of Dalpiciclib Plus Letrozole and Capecitabine of First-line Treatment With High-risk HR- Positive /HER-2 Negative Advanced Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Fujian Medical University Union Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer

Detailed description

The purpose of the study is to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with high-risk for HR- positive /HER-2 negative advanced breast cancer

Conditions

• Advanced Breast Cancer

Interventions

Type	Name	Description
DRUG	Dalpiciclib+ letrozole +capecitabine	Continue medication to disease progression

Timeline

• Start date: 2022-08-10
• Primary completion: 2023-08-01
• Completion: 2024-08-01
• First posted: 2022-07-22
• Last updated: 2022-07-22